Credit Suisse Ag Bluebird Bio, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$1.32 - $4.83 $2.26 Million - $8.28 Million	-1,714,040 Reduced 96.04%	70,640 $97,000
Q3 2023 Nov 13, 2023	SELL	$3.02 - $4.05 $202,726 - $271,868	-67,128 Reduced 3.62%	1,784,680 $5.43 Million
Q2 2023 Aug 11, 2023	BUY	$2.79 - $5.03 $456,399 - $822,827	163,584 Added 9.69%	1,851,808 $6.09 Million
Q1 2023 May 10, 2023	BUY	$3.14 - $8.22 $102,649 - $268,720	32,691 Added 1.97%	1,688,224 $5.37 Million
Q4 2022 Feb 13, 2023	BUY	$5.77 - $8.49 $393,444 - $578,916	68,188 Added 4.3%	1,655,533 $11.5 Million
Q3 2022 Nov 10, 2022	SELL	$3.75 - $7.39 $60,030 - $118,299	-16,008 Reduced 1.0%	1,587,345 $10 Million
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $1.77 Million - $3.15 Million	-601,410 Reduced 27.28%	1,603,353 $6.64 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $22,246 - $57,939	5,466 Added 0.25%	2,204,763 $10.7 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $1.75 Million - $3.18 Million	195,005 Added 9.73%	2,199,297 $22 Million
Q3 2021 Nov 12, 2021	SELL	$11.24 - $21.0 $7.1 Million - $13.3 Million	-631,349 Reduced 23.95%	2,004,292 $38.3 Million
Q2 2021 Aug 16, 2021	BUY	$18.04 - $22.09 $5.67 Million - $6.94 Million	314,201 Added 13.53%	2,635,641 $84.3 Million
Q1 2021 May 14, 2021	BUY	$16.59 - $33.89 $13.5 Million - $27.6 Million	812,964 Added 53.89%	2,321,440 $70 Million
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $23.3 Million - $32.1 Million	846,670 Added 127.93%	1,508,476 $65.3 Million
Q3 2020 Nov 13, 2020	SELL	$34.44 - $43.75 $218,866 - $278,031	-6,355 Reduced 0.95%	661,806 $35.7 Million
Q2 2020 Aug 12, 2020	BUY	$27.12 - $45.97 $4.78 Million - $8.1 Million	176,114 Added 35.79%	668,161 $40.8 Million
Q1 2020 May 13, 2020	BUY	$26.16 - $63.5 $3.67 Million - $8.91 Million	140,289 Added 39.88%	492,047 $22.6 Million
Q4 2019 Feb 12, 2020	SELL	$46.96 - $61.67 $8.27 Million - $10.9 Million	-176,066 Reduced 33.36%	351,758 $30.9 Million
Q3 2019 Nov 12, 2019	BUY	$59.47 - $93.1 $10.5 Million - $16.5 Million	176,791 Added 50.36%	527,824 $48.5 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $2.75 Million - $3.81 Million	36,249 Added 11.52%	351,033 $44.7 Million
Q1 2019 May 14, 2019	SELL	$64.44 - $104.11 $2.55 Million - $4.13 Million	-39,648 Reduced 11.19%	314,784 $49.5 Million
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $5.6 Million - $8.83 Million	94,694 Added 36.46%	354,432 $35.2 Million
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $4.84 Million - $6.4 Million	54,498 Added 26.55%	259,738 $37.9 Million
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $5.96 Million - $7.64 Million	-59,848 Reduced 22.58%	205,240 $32.2 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $11.2 Million - $16 Million	106,282 Added 66.93%	265,088 $45.3 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $4.34 Million - $6.99 Million	53,475 Added 50.77%	158,806 $28.3 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $873,432 - $1.38 Million	15,127 Added 16.77%	105,331 $14.5 Million
Q2 2017 Aug 14, 2017	BUY	N/A	90,204	90,204 $9.48 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.71 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.88 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.73 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.73 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.42 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account